Navigation Links
InterMune to Present at Deutsche Bank Biotech Boston Confab
Date:11/7/2008

BRISBANE, Calif., Nov. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at Deutsche Bank's 2008 Biotech Boston Confab on November 11, 2008 at 4:00 p.m. EST.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
2. InterMune to Release Third Quarter 2008 Financial Results on November 6
3. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
4. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
5. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
6. InterMune to Present at Canaccord Adams Conference
7. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
8. InterMune to Present at BMO Healthcare Conference
9. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
10. InterMune to Present at Jefferies Healthcare Conference
11. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2020)... ... June 23, 2020 , ... Nobilis Therapeutics, a biopharmaceutical ... has filed an Investigational New Drug application (IND) with the U.S. Food & ... drug candidate NBTX-001 in patients with panic disorder (PD). , "Adding a PD ...
(Date:6/11/2020)... ... June 09, 2020 , ... Reducing carbon emissions has been and will continue ... to stock market dips, ways to reduce CO2 is something we can’t avoid. ... of the biofuels being produced today are created from recycled cooking oil or crops. ...
(Date:5/28/2020)... BASEL, Switzerland (PRWEB) , ... May 28, 2020 ... ... for biopharmaceutical R&D, today announced the release of Genedata Screener ® 17.0, ... management of screening data from all in-vitro screening assay technologies. Genedata will host ...
(Date:5/21/2020)... ... May 19, 2020 , ... Eaton Square is pleased to announce its ... Company, a biotechnology and medical technology-focused strategy and M&A advisory firm. , This is ... States, linking US and Asia Pacific healthcare innovators with capital and investors. , Popper ...
Breaking Biology Technology:
(Date:7/1/2020)... ... 01, 2020 , ... Catalent, a global leader in clinical ... packaging facility in Minakuchi, located in the Shiga prefecture of Japan. , Operating ... the new 60,000-square-foot facility will provide customers with flexible clinical supply solutions, serving ...
(Date:6/25/2020)... MANSFIELD, Mass. (PRWEB) , ... June 24, 2020 ... ... provider of cloud-based enterprise software and software-driven clinical data services that accelerate drug ... trials for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. ...
(Date:6/23/2020)... , ... June 23, 2020 , ... ... is pleased to announce the next event in a series of TOPIQ webinars, ... The TOPIQ series of webinars was developed in response to social distancing measures ...
Breaking Biology News(10 mins):